Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.

NCT06157151 is registered in ClinicalTrials.gov with Precigen, Inc as lead sponsor.

NCT NCT06157151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.
Lead sponsor
Precigen, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
November 11, 2025
Completion date
November 30, 2030
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, hpv-related carcinoma, hpv-related malignancy, metastatic cervical cancer, recurrent cervical carcinoma